FAKTOR-OPTIONSSCHEIN - INCYTE CO. Stock

DE000SD42FK1

Market Closed - Boerse Frankfurt Warrants 15:45:17 2024-05-17 EDT
2.96 ^EUR	+1.02%

Current month	+17.93%
1 month	+12.12%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart INCYTE CORPORATION

Latest news about INCYTE CORPORATION

Transcript : Incyte Corporation Presents at Bank of America Health Care Conference 2024, May-15-2024 08:00 AM	05-15
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress	05-14	BU
Equities Close Mixed as Markets Weigh Consumer Inflation Survey	05-13	MT
Equities Close Mixed as Markets Parse Consumer Inflation Survey	05-13	MT

More news

Quotes 5-day view

Date	Price	Change
24-05-17	2.96	+1.02%
24-05-16	2.93	-1.35%
24-05-15	2.97	0.00%
24-05-14	2.97	-1.66%
24-05-13	3.02	+16.15%

Real-time Boerse Frankfurt Warrants

Last update May 17, 2024 at 03:45 pm

More quotes

Static data

Product type	Exotic Products
Buy / Sell	CALL
Underlying	INCYTE CORPORATION
Issuer	Société Générale
WKN	SD42FK
ISIN	DE000SD42FK1
Date issued	2021-03-29
Strike	79.94 $
Maturity	Unlimited
Parity	1 : 1
Emission price	8.55 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	9.37 €
Lowest since issue	2.37 €
Spread	0.01 €
Spread %	0.34%

Company Profile

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

More about the company

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: Incyte Corporation

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

57.1 USD

Average target price

73.35 USD

Spread / Average Target

+28.46%

Consensus